Agenus Inc. (AGEN)
NASDAQ
Closed
Oct 8, 2026
Day's Range
7.2452 wk Range
2.71Overview - AGEN - Agenus Inc.
Key Statistics
Valuation
Enterprise Value
352.39M
P/E (Trailing)
‪2.96‬
P/E (Forward)
‪-68.09‬
PEG Ratio
‪-0.02‬
Price / Sales (TTM)
‪2.54‬
Price / Book
‪-1.51‬
EV / EBITDA
‪8.67‬
Profitability
Gross Margin
‪57.24%‬
Profit Margin
‪69.34%‬
Operating Margin
‪32.71%‬
Return on Assets
‪12.53%‬
Return on Equity
‪0.03%‬
Ownership
Shares Outstanding
44.75M
Float
40.22M
Short % of Shares Outstanding
‪15.24%‬
Held by Insiders
‪6.26%‬
Held by Institutions
‪46.37%‬
Price stats
Beta
‪1.32‬
50-Day Avg
‪7.80‬
200-Day Avg
‪4.64‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
3 analysts
Average price target
‪$ 19.50‬Shariah Compliance
Report Date: Feb 19, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - AGEN - Agenus Inc.
Peers - AGEN - Agenus Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- AGENNASDAQAgenus Inc.341.87MMarket Cap+43.86%52-week change2.96P/E (Trailing)‪69.34%‬Profit Margin
- ARGXNASDAQArgenx SE57.50BMarket Cap+14.28%52-week change34.96P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.29.40BMarket Cap-105.72%52-week change38.35P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share24.34BMarket Cap-8.52%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S14.99BMarket Cap+7.48%52-week change17.72P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.14BMarket Cap+18.80%52-week change-17.80P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.11.06BMarket Cap+2.75%52-week change154.54P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - AGEN - Agenus Inc.
About
Agenus Inc. is a clinical-stage biotechnology company focused on immuno-oncology and immune-based therapies for cancer. Agenus develops a pipeline of checkpoint antibodies, immune modulators, and combination regimens designed to help the immune system recognize and attack tumors. Its current portfolio also includes…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
